ACP‑105 | 35mg/1,5ml

What is ACP‑105?

ACP-105 is a synthetic selective androgen receptor modulator (SARM) developed to provide a pronounced anabolic effect with significantly limited systemic impact on organs sensitive to androgen stimulation. The compound is among the most innovative molecules in its class and is distinguished by high affinity for receptors in skeletal muscle and bone tissue, without activating other hormonal pathways that could lead to adverse reactions.

ACP-105 has attracted the attention of the scientific community with promising observations related to increases in lean muscle mass, improvements in bone density, and restoration of functional strength in models subjected to muscle atrophy or hormonal deficiency. Thanks to its precise molecular structure and high tissue selectivity, ACP-105 is considered a potential tool for research in sarcopenia, osteoporosis, and physical rehabilitation.

Mechanism of action of ACP‑105:

ACP-105 binds with high selectivity to androgen receptors in specific tissues, especially skeletal muscle and bones. After binding, it activates the transcription of genes responsible for muscle protein synthesis, cell regeneration, and mineral density. Its mechanism is designed to avoid systemic androgenic activity—for example, on prostate tissue—by focusing on anabolic processes without the accompanying side effects typical of classical hormonal preparations.

An additional advantage of ACP-105 is that it does not interact with systems responsible for the production of estrogens or other hormones, which minimizes the risk of secondary hormonal deviations. This enables its use in research models aimed at studying isolated effects on the musculoskeletal system without interference in overall endocrine regulation.

Potential scientifically supported benefits of ACP‑105:

• Stimulation of muscle hypertrophy with maintained low androgenic load;
• Improvement of bone structure and density, especially in models with induced osteopenia;
• Support for regeneration after muscle injury or loss of mass;
• Improved functional strength and load-bearing resilience;
• High tissue selectivity with limited impact on other organs;
• Stable formulation for subcutaneous administration, ensuring a predictable pharmacokinetic profile.

Thanks to these characteristics, ACP-105 is used in scientific models that aim to explore options for maintaining musculoskeletal function under conditions of aging, immobilization, or hormonal deficiency.

Comparison of ACP-105 with other SARMs

ACP-105 is a selective androgen receptor modulator that stands out with high receptor selectivity and moderate anabolic action, with minimal impact on non-target tissues. Although less well known than leading molecules such as Ligandrol (LGD-4033), Ostarine (MK2866), and S23, ACP-105 is viewed as a balanced alternative for studies requiring lower androgenic load and good tolerability.

Compared with Ostarine, ACP-105 offers similar anabolic activity but with a possibly faster onset, according to some preclinical observations. Both molecules are suitable for maintaining muscle mass in deficiency or immobilization, with ACP-105 potentially offering a slight advantage in short-term protocols where a moderate but distinct result is sought.

Compared with Ligandrol, ACP-105 shows a less pronounced pure anabolic effect but also a lower risk of suppressing the hormonal axis. While LGD-4033 is preferred in aggressive muscle-oriented protocols, ACP-105 is more often used in supportive research related to recovery, mobility, and bone structure, especially in more sensitive models.

Compared with S23, which is extremely potent and often leads to testosterone suppression, ACP-105 is significantly more sparing, without the need for intensive post-protocol hormonal control. It is suitable for laboratory settings where anabolic efficiency with minimal systemic risk is sought.

Dosage and application of ACP-105 in research protocols:

Recommended research schedule: 5 units once daily, for 4–6 weeks, followed by a 2–4 week off period.

1 unit = 23.33mcg.

Total amount in pen: 150 units

Possible side effects of ACP‑105:

• Temporary suppression of endogenous androgen production;
• Variable individual sensitivity to receptor stimulation;
• Insufficient data regarding safety during prolonged application.

Adhering to optimal dosing and controlling the duration of application play a key role in limiting the manifestation of side effects.

Disclaimer

For research use only. Not for human consumption.